News & Updates
Filter by Specialty:
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
Treatment with bezlotoxumab results in a significant decrease in recurrent Clostridioides difficile infection (CDI) in a cohort of immunocompromised patients and transplant recipients, reports a study.
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
16 Jul 2023
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
15 Jul 2023
Danuglipron helps with glucose control, weight loss in T2D
The glucagon-like peptide 1 receptor (GLP-1R) agonist danuglipron appears to be beneficial in the treatment of patients with type 2 diabetes (T2D), yielding reductions in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight, without fasting restrictions, as shown in the results of a phase IIb study.
Danuglipron helps with glucose control, weight loss in T2D
15 Jul 2023
Long-acting ART induces viral suppression in people with HIV
People with HIV (PWH) who are treated with long-acting (LA) antiretroviral therapy (ART) achieve virologic suppression, as do those with viraemia and challenges to adherence, reports a study.
Long-acting ART induces viral suppression in people with HIV
15 Jul 2023
Patient preferences must be considered for anticoagulation duration in unprovoked VTE
Shared decision making should be practiced by clinicians to include patient preferences and values when taking into account the duration of anticoagulant therapy for unprovoked venous thromboembolism (VTE), suggests a study.
Patient preferences must be considered for anticoagulation duration in unprovoked VTE
14 Jul 2023
Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis
Asian patients with moderate to severe plaque psoriasis may benefit from ustekinumab therapy, which has been shown to be both safe and effective in a Singapore study.